[go: up one dir, main page]

RU94036758A - Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома - Google Patents

Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома

Info

Publication number
RU94036758A
RU94036758A RU94036758/14A RU94036758A RU94036758A RU 94036758 A RU94036758 A RU 94036758A RU 94036758/14 A RU94036758/14 A RU 94036758/14A RU 94036758 A RU94036758 A RU 94036758A RU 94036758 A RU94036758 A RU 94036758A
Authority
RU
Russia
Prior art keywords
phenyl
aroylbenzothiophenes
peri
group
menopause syndrome
Prior art date
Application number
RU94036758/14A
Other languages
English (en)
Inventor
Джозеф Каллинан Джордж
Us]
Дэвид Термайн Джон
Original Assignee
Эли Лилли энд Компани (US)
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли энд Компани (US), Эли Лилли Энд Компани filed Critical Эли Лилли энд Компани (US)
Publication of RU94036758A publication Critical patent/RU94036758A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Способ лечения пери-менопаузного синдрома, предусматривающий введение человеку, нуждающемуся в лечении, эффективного количества соединения, имеющего формулу, приведенную в описании, или их фармацевтически приемлемой соли или сольвата.

Claims (1)

  1. Способ лечения пери-менопаузного синдрома, предусматривающий введение человеку, нуждающемуся в лечении, эффективного количества соединения, имеющего формулу, приведенную в описании, или их фармацевтически приемлемой соли или сольвата.
RU94036758/14A 1993-10-15 1994-10-13 Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома RU94036758A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/138,287 1993-10-15
US08/138,287 US5391557A (en) 1993-10-15 1993-10-15 Methods for the treatment of peri-menopausal syndrome

Publications (1)

Publication Number Publication Date
RU94036758A true RU94036758A (ru) 1996-08-27

Family

ID=22481346

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94036758/14A RU94036758A (ru) 1993-10-15 1994-10-13 Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома

Country Status (20)

Country Link
US (1) US5391557A (ru)
EP (1) EP0652001B1 (ru)
JP (1) JPH07196499A (ru)
KR (1) KR950010890A (ru)
CN (1) CN1107157A (ru)
AT (1) ATE153240T1 (ru)
AU (1) AU670394B2 (ru)
CA (1) CA2118093A1 (ru)
CZ (1) CZ253394A3 (ru)
DE (1) DE69403305T2 (ru)
DK (1) DK0652001T3 (ru)
ES (1) ES2104285T3 (ru)
GR (1) GR3023603T3 (ru)
HU (1) HUT71229A (ru)
IL (1) IL111290A (ru)
NO (1) NO943876L (ru)
NZ (1) NZ264673A (ru)
PH (1) PH31262A (ru)
RU (1) RU94036758A (ru)
ZA (1) ZA948024B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
CA2162586C (en) 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US6417198B1 (en) * 1993-12-21 2002-07-09 Eli Lilly And Company Methods of inhibiting CNS problems in post-menopausal women
US5534526A (en) * 1993-12-21 1996-07-09 Eli Lilly And Company Methods for inhibiting vasomotor symptoms and attending psychological disturbances surrounding post-menopausal syndrome
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5514704A (en) * 1995-03-13 1996-05-07 Eli Lilly And Company Benzothiophenes to inhibit leukotrienes
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
AU5554996A (en) * 1995-04-21 1996-11-07 Eli Lilly And Company Benzothiophenes with novel basic side chains
AU6277396A (en) * 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
WO1997001549A1 (en) * 1995-06-26 1997-01-16 Eli Lilly And Company Benzothiophene compounds
EA001103B1 (ru) * 1996-01-29 2000-10-30 Эли Лилли Энд Компани Способы повышения компетенции сфинктера
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
WO1998046588A2 (en) * 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US6008232A (en) * 1997-08-20 1999-12-28 Eli Lilly And Company Methods for preventing headaches
AU9106198A (en) * 1997-08-21 1999-03-08 Eli Lilly And Company Methods for inhibiting temporomandibular disorders
US6103740A (en) * 1997-08-21 2000-08-15 Eli Lilly And Company Methods for lowering platelet counts
WO1999008523A1 (en) * 1997-08-21 1999-02-25 Eli Lilly And Company Methods for inhibiting fibrous inflammatory disease and riedel's thyroiditis
US6096781A (en) * 1997-11-14 2000-08-01 Eli Lilly And Company 2-arylbenzo[B]thiophenes useful for the treatment of estrogen deprivation syndrome
FR2777784B1 (fr) * 1998-04-27 2004-03-19 Arepa Composition pharmaceutique a base d'estrogene et de progesterone
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6258826B1 (en) 1998-10-13 2001-07-10 Eli Lilly And Company Pharmaceutical formulations and applications thereof for the treatment of estrogen deprivation syndrome
RO122180B1 (ro) * 1999-08-31 2009-02-27 Jenapharm Gmbh & Co. Kg Utilizarea mezoprogestinelor în terapia de substituţie hormonală
US6376242B1 (en) 1999-09-21 2002-04-23 Emory University Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
DE60108710T2 (de) * 2000-11-30 2006-05-04 Pfizer Products Inc., Groton Östrogen Agonist-Antagonist und Testosteron enthaltende Zusammensetzung zur Behandlung abnehmender Testosteronspiegel
AU781168B2 (en) * 2001-01-26 2005-05-12 Pfizer Products Inc. Method of treating certain cancers using an estrogen agonist/antagonist
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
US4380635A (en) * 1981-04-03 1983-04-19 Eli Lilly And Company Synthesis of acylated benzothiophenes
US5075321A (en) * 1987-03-24 1991-12-24 University Of Pennsylvania Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes
DE4122484A1 (de) * 1991-07-06 1993-01-07 Teves Gmbh Alfred Schaltungsanordnung zur erkennung von radsensordefekten
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体

Also Published As

Publication number Publication date
HU9402956D0 (en) 1995-02-28
NO943876L (no) 1995-04-18
CA2118093A1 (en) 1995-04-16
CN1107157A (zh) 1995-08-23
US5391557A (en) 1995-02-21
DE69403305T2 (de) 1997-09-25
ATE153240T1 (de) 1997-06-15
ES2104285T3 (es) 1997-10-01
JPH07196499A (ja) 1995-08-01
NZ264673A (en) 1999-08-30
EP0652001B1 (en) 1997-05-21
NO943876D0 (no) 1994-10-13
PH31262A (en) 1998-06-18
GR3023603T3 (en) 1997-08-29
CZ253394A3 (en) 1995-05-17
ZA948024B (en) 1996-04-15
DE69403305D1 (de) 1997-06-26
IL111290A (en) 1999-04-11
AU670394B2 (en) 1996-07-11
KR950010890A (ko) 1995-05-15
AU7579094A (en) 1995-05-04
EP0652001A1 (en) 1995-05-10
HUT71229A (en) 1995-11-28
DK0652001T3 (da) 1997-09-15
IL111290A0 (en) 1994-12-29

Similar Documents

Publication Publication Date Title
RU94036758A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения пери-менопаузного синдрома
RU94036772A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
RU94044453A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования себореи и угрей
RU94045149A (ru) Средство ингибирования легочных гипертонических заболеваний
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
RU94044488A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования симптомов пременструального синдрома/ дисфории, связанной с поздней лютеальной фазой
RU94045155A (ru) Способы ингибирования болезни альцгеймера
RU94044454A (ru) Ингибитор аутоимунных заболеваний
RU94022258A (ru) Новые сульфониламинопиримидины
RU94045278A (ru) Применение 2-фенил-3-ароилбензтиофенов для ингибирования вазомоторных симптомов и сопутствующих психологических нарушений, ассоциированных с постклимактерическим синдромом
RU94036771A (ru) Ингибиторы ангиогенеза и ангиогенных заболеваний
RU94044490A (ru) Применение 2-фенил-3-ароилбензотиофенов для подавления дефектного восстановления ткани
GB0225475D0 (en) Therapeutic agents
DE69616749D1 (de) Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe
RU94037246A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща
RU94044677A (ru) Трехзамещенные фенильные производные, способ получения, фармацевтическая композиция
BR9709823B1 (pt) "compostos de amidas de ácido alqueno piridílico e alquino piridílico, métodos de preparação e uso dos mesmos, bem como medicamento".
RU94037233A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения лекарственноустойчивых новообразований
RU94044456A (ru) Средство для подавления дисфункционального маточного кровотечения
RU94044321A (ru) Средство повышения либидо у женщин постклимактерического периода
RU94037235A (ru) Ингибитор фиброза матки
RU94022743A (ru) Амидо- или карбамидо-производные, обладающие антигиперхолестериновой активностью, и фармацевтическая композиция на их основе
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с